Most people diagnosed with chronic inflammatory demyelinating polyneuropathy receive the news alongside a bewildering list of treatment acronyms: IVIG, SCIg, plasma exchange, FcRn blockers. The condition itself is already complex enough. CIDP is an autoimmune disorder in which the immune system attacks the myelin sheath surrounding peripheral nerves, causing progressive muscle weakness, numbness, and balance problems that can significantly affect daily life. What patients often need most is a clear, honest explanation of how infusion treatment actually works, what the options look like today, and what to realistically expect from the process. This article delivers exactly that.
What Is CIDP and Why Does It Require Infusion Therapy?
CIDP infusion treatment targets the underlying immune dysfunction driving nerve damage, rather than simply masking symptoms. Medications and therapies for CIDP focus on modifying immune responses to halt or slow demyelination and inflammation, promoting nerve repair and function. Because the condition is chronic and relapsing, most patients require ongoing treatment rather than a single course of therapy.
CIDP is a rare autoimmune disorder that damages peripheral nerves, leading to muscle weakness, numbness, and impaired function. Intravenous immunoglobulin (IVIG) has emerged as an effective therapy, providing targeted antibodies to reduce inflammation and support nerve repair.
The reason infusion therapy sits at the centre of CIDP management is mechanistic. IVIG is an antibody-based therapy that uses antibodies from multiple donors to create a sterile infusion that helps regulate a person’s immune response rather than simply boosting it. While the exact mechanisms of IVIG are not fully understood, experts know that antibodies in IVIG bind to autoantibodies in CIDP, helping reduce related inflammation and prevent demyelination. This is not a blunt immunosuppressant approach. It is a targeted immunomodulatory strategy, which is why IVIG for CIDP carries a specific FDA-approved indication rather than off-label status for most named products.
Patients who present with disabling symptoms are typically started on treatment promptly. Joint guidelines from the European Academy of Neurology and the Peripheral Nerve Society (EAN/PNS) continue to recommend intravenous immunoglobulin or systemic corticosteroids as first-line treatment for CIDP with disabling symptoms. The choice between those two first-line options depends on the individual patient’s profile, comorbidities, and the treating neurologist’s clinical judgement.
IVIG for CIDP: Loading Doses, Maintenance Schedules, and Named Products
IVIG therapy for CIDP follows a two-phase protocol that distinguishes it from many other infusion treatments. Understanding the difference between the induction phase and long-term maintenance helps patients set realistic expectations and plan around their schedules.
The Loading Dose
Initial IVIG therapy typically involves a loading dose of 2 grams per kilogram of body weight, administered over two to five days. This approach aims to rapidly suppress autoimmune activity and stabilise symptoms. While some patients notice improvement within days to weeks, maximum benefit may take several months to achieve. For a patient weighing 80 kg, that translates to 160 g of immunoglobulin delivered across multiple clinic visits, each session lasting several hours.
Maintenance Therapy
Maintenance therapy follows, generally ranging from 0.4 to 1 gram per kilogram every three to four weeks. Individual response determines the exact schedule: some patients maintain remission with less frequent dosing, while others require more regular infusions. In practice, neurologists frequently adjust both dose and interval over time, titrating to the lowest effective dose that keeps symptoms controlled.
Which IVIG Products Are Used?
Several FDA-approved IVIG products carry a specific CIDP indication. The table below summarises the most commonly prescribed options and their labelled dosing parameters.
| Product | Route | Loading Dose | Maintenance Dose | CIDP Indication |
|---|---|---|---|---|
| Gamunex-C | IV only | 2 g/kg over 2–5 days | 1 g/kg every 3 weeks | ✅ Loading + maintenance |
| Privigen | IV only | 2 g/kg over 2–5 days | 1 g/kg every 3 weeks | ✅ Loading + maintenance |
| Gammagard Liquid | IV only | 2 g/kg over 2–5 days | 1 g/kg every 3 weeks over 1–4 days | ✅ Loading + maintenance |
| Hizentra | Subcutaneous | ❌ Not indicated | Maintenance only (prevent relapse) | ⚠️ Maintenance only |
| HyQvia | Subcutaneous | ❌ Not indicated | Maintenance only | ⚠️ Maintenance only |
A clinically important distinction: on the Gamunex-C and Gammaked labels, CIDP is an intravenous-only indication. Two subcutaneous immunoglobulin products carry a narrower CIDP indication limited to maintenance. Hizentra is labelled for CIDP “as maintenance therapy to prevent relapse,” and HyQvia was approved by the FDA on 16 January 2024 for CIDP maintenance therapy in adults. Neither subcutaneous product is labelled for the initial loading course.
Beyond IVIG: The Newest Biologic Option for CIDP
The treatment landscape for chronic inflammatory demyelinating polyneuropathy expanded significantly with a recent regulatory milestone. Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is the first and only neonatal Fc receptor (FcRn) blocker approved for treating CIDP. The FDA’s approval was based on a clinical study (ADHERE) in which 69% of patients treated with Vyvgart Hytrulo showed evidence of clinical improvement, regardless of whether they had prior treatment, including improvements in mobility, function, and strength.
Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor, resulting in reduction of circulating IgG. Because IgG autoantibodies are central to the nerve damage seen in CIDP, reducing their circulating levels addresses the disease at a mechanistic level rather than simply flooding the system with competing antibodies as IVIG does.
Vyvgart Hytrulo is the first and only neonatal Fc receptor blocker approved for the treatment of CIDP, and is available as a once-weekly, 30- to 90-second subcutaneous injection. For patients who find multi-hour IV infusion sessions burdensome, this represents a meaningful shift in how outpatient CIDP treatment can be structured. The ADHERE trial, the largest clinical trial to date studying CIDP, met its primary endpoint in demonstrating a 61% reduction in the risk of relapse versus placebo.
It is worth noting that Vyvgart Hytrulo is not a replacement for IVIG in every patient. Neurologists currently use clinical response, tolerability, venous access challenges, and patient lifestyle factors to determine which approach best suits each individual. Some patients may transition from IVIG to an FcRn blocker; others may remain on IVIG long-term with excellent results.
What to Expect During Outpatient CIDP Infusion Treatment
Outpatient CIDP treatment at a dedicated infusion centre is designed to be medically supervised and clinically rigorous without the disruption, cost, or institutional atmosphere of a hospital setting. Knowing what happens at each stage of a session removes much of the anxiety that accompanies a first infusion appointment.
Before the Infusion Starts
On arrival at an infusion therapy centre, a nurse will review current medications, check vitals, and confirm the prescription and dose with the treating physician’s orders. Pre-medications, often acetaminophen and diphenhydramine (Benadryl), are commonly given to reduce the risk of infusion-related reactions such as headache, chills, or flushing. Patients with a history of migraines or prior headache reactions to IVIG may receive additional prophylactic treatment.
During the Session
Once the IV line is placed, the infusion begins slowly. The infusion starts slowly, with the nurse monitoring vital signs closely including blood pressure, heart rate, and temperature. If the patient tolerates it well, the rate is gradually increased. Maintenance infusions for an established patient typically run two to four hours. Loading-dose sessions, spread across multiple consecutive days, may each last somewhat longer depending on the total dose and the patient’s tolerance of the infusion rate.
Staying well-hydrated is crucial. IVIG can be viscous, and being well-hydrated helps it flow better and reduces the risk of headaches afterwards. Patients are encouraged to bring something to occupy their time. Many infusion centres provide reclining chairs, blankets, and a calm environment that bears little resemblance to a busy hospital ward.
Common Side Effects and How They Are Managed
Common side effects include headache, fatigue, chills, and muscle aches, often occurring during or immediately after the infusion. These can usually be managed by slowing the infusion rate, proper hydration, and pre-medication. Serious side effects like blood clots or kidney issues are rare but possible. Patients with pre-existing risk factors for thrombosis or renal impairment should discuss these with their neurologist before starting IVIG. For individuals at risk of renal dysfunction or renal failure, IVIG should be administered at the minimum dose and infusion rate practicable, and adequate hydration should be ensured before administration.
Response timelines vary between individuals. Some patients report feeling stronger within one to two weeks after their initial loading dose. For others, it may take up to three to six months of regular maintenance therapy to see the full benefit. Neurologists typically reassess at regular intervals, adjusting the maintenance dose and schedule based on objective functional measures and patient-reported symptoms.
Frequently Asked Questions About CIDP Infusion Treatment
Is IVIG a cure for CIDP?
No. IVIG for CIDP is an immunomodulatory therapy that controls the autoimmune activity driving nerve damage. It does not cure the underlying condition. Many patients require ongoing maintenance infusions to prevent relapse and preserve nerve function. Some achieve stable remission and may be able to extend dosing intervals over time, but this is determined on an individual basis.
Can CIDP infusion therapy be given outside of a hospital?
Yes, and for most stable patients it is the preferred setting. Standalone outpatient infusion centres offer the same clinical supervision as hospital outpatient departments but in a more comfortable, cost-effective environment. An infusion centre is an outpatient clinic certified to administer infusion therapy, often a comfortable setting staffed with specialists in infusion therapy. Insurance plans increasingly support non-hospital sites of care for IVIG administration.
How long does a CIDP maintenance infusion take?
Infusions usually last two to four hours from start to finish. Loading-dose sessions administered across consecutive days may run slightly longer depending on the individual dose and the rate at which the product is tolerated. Patients should plan for a half-day commitment per session, particularly for the first few visits while the infusion rate is being established.
What is the difference between IVIG and subcutaneous immunoglobulin for CIDP?
IVIG is delivered intravenously at an infusion centre and is appropriate for both the loading phase and maintenance. Subcutaneous immunoglobulin (SCIg), such as Hizentra or HyQvia, is labelled only for maintenance in CIDP and can in some cases be self-administered at home after training. Compared to the IV route, the subcutaneous route maintains higher trough levels of immunoglobulins, increases patient independence, and reduces systemic side effects. The right choice depends on the patient’s clinical status, venous access, and lifestyle.
Key Takeaways for Patients Starting CIDP Infusion Therapy
- CIDP infusion treatment is evidence-based and FDA-approved for several named IVIG products, including Gamunex-C, Privigen, and Gammagard Liquid.
- Treatment follows two distinct phases: a higher loading dose administered over two to five days, followed by regular maintenance infusions typically every three weeks.
- A newer biologic option, Vyvgart Hytrulo (efgartigimod alfa), is now FDA-approved as the first FcRn blocker for CIDP, offering a once-weekly subcutaneous injection alternative.
- Common side effects such as headache and fatigue are manageable through hydration, pre-medication, and careful infusion rate titration.
- Outpatient infusion centres provide clinical-grade supervision in a more accessible, lower-cost setting than hospital-based care.
- Response to therapy varies: some patients improve within weeks, while others need several months of consistent treatment to see meaningful benefit.
- Patients are encouraged to track symptoms between sessions and communicate openly with their infusion team to allow timely dose adjustments.
For patients navigating a new CIDP diagnosis, understanding the treatment options is the first step toward regaining control. Whether the path forward involves CIDP IVIG therapy at a dedicated infusion centre, a transition to subcutaneous maintenance dosing, or one of the newer biologic mechanisms, the most important factor is receiving that care in a setting where clinical expertise, comfort, and coordination with the referring neurologist are all prioritised. Thrivewell Infusion’s multi-state network of outpatient infusion centres is designed precisely for patients who need that standard of care, without the complexity and cost of hospital-based treatment. Learn more about current CIDP treatment options or explore the clinical evidence supporting IVIG initiation in CIDP to inform your next conversation with your neurologist.